COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs.
作者： Jane A. Mitchell , Timothy D. Warner
DOI: 10.1038/NRD1929
关键词:
摘要: Cyclooxygenase-2-selective drugs were designed to be safer alternatives traditional NSAIDs. However, concerns that they increase the risk of thrombotic events have led withdrawal some these drugs. Mitchell and Warner discuss their underlying mechanisms actions. Non-steroidal anti-inflammatory (NSAIDs) inhibit formation prostanoids by enzyme cyclooxygenase (COX). Work in past 15 years has shown COX exists two forms: COX1, which is largely associated with physiological functions, COX2, pathological functions. Heated debate followed introduction selective COX2 inhibitors around 5 ago: do offer any advantages over NSAIDs meant replace, particularly regard gastrointestinal cardiovascular side effects? Here we evidence latest recommendations for use as well
nature.com
sci-hub.se 参考文章(129)
Murray Epstein, Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction Journal of Hypertension. ,vol. 20, ,(2002)
IA Reilly, GA FitzGerald, Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. ,vol. 69, pp. 180- 186 ,(1987) , 10.1182/BLOOD.V69.1.180.BLOODJOURNAL691180
D.A. Kujubu, B.S. Fletcher, B.C. Varnum, R.W. Lim, H.R. Herschman, TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue Journal of Biological Chemistry. ,vol. 266, pp. 12866- 12872 ,(1991) , 10.1016/S0021-9258(18)98774-0
Takahiko Murata, Fumitaka Ushikubi, Toshiyuki Matsuoka, Masakazu Hirata, Atsushi Yamasaki, Yukihiko Sugimoto, Atsushi Ichikawa, Yoshiya Aze, Takashi Tanaka, Nobuaki Yoshida, Akinori Ueno, Sachiko Oh-ishi, Shuh Narumiya, Altered pain perception and inflammatory response in mice lacking prostacyclin receptor Nature. ,vol. 388, pp. 678- 682 ,(1997) , 10.1038/41780
Mason W Russell, Dan Pettitt, Gurkirpal Singh, Ralph B D'Agostino, Jeffrey D Miller, Daniel M Huse, Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. The Journal of Rheumatology. ,vol. 30, pp. 714- 719 ,(2003)
Kenneth C. Lasseter, Francesca Catella-Lawson, Briggs W. Morrison, Barry J. Gertz, Shiv Kapoor, Garret A. Fitzgerald, Brendan McAdam, Dean Kujubu, Hui Quan, Lisa Antes, Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. Journal of Pharmacology and Experimental Therapeutics. ,vol. 289, pp. 735- 741 ,(1999)
LORNA C. HAMILTON, JANE A. MITCHELL, ANNETTE M. TOMLINSON, TIMOTHY D. WARNER, Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy The FASEB Journal. ,vol. 13, pp. 245- 251 ,(1999) , 10.1096/FASEBJ.13.2.245
Glenn D. Rosen, Thomas M. Birkenmeier, Ami Raz, Michael J. Holtzman, Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation Biochemical and Biophysical Research Communications. ,vol. 164, pp. 1358- 1365 ,(1989) , 10.1016/0006-291X(89)91819-6
Christopher S. R. Baker, Roger J. C. Hall, Thomas J. Evans, Ariela Pomerance, Jacques Maclouf, Christophe Creminon, Magdi H. Yacoub, Julia M. Polak, Cyclooxygenase-2 Is Widely Expressed in Atherosclerotic Lesions Affecting Native and Transplanted Human Coronary Arteries and Colocalizes With Inducible Nitric Oxide Synthase and Nitrotyrosine Particularly in Macrophages Arteriosclerosis, Thrombosis, and Vascular Biology. ,vol. 19, pp. 646- 655 ,(1999) , 10.1161/01.ATV.19.3.646
Eric J. Topol, Failing the public health--rofecoxib, Merck, and the FDA. The New England Journal of Medicine. ,vol. 351, pp. 1707- 1709 ,(2004) , 10.1056/NEJMP048286